International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
about
Pomalidomide for the treatment of multiple myelomaInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationRecent advances in multiple myeloma: a Korean perspectiveAutologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing CountryQuisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.Bortezomib in multiple myeloma: systematic review and clinical considerations.Immunomodulatory drugs in multiple myeloma.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma.Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trialsTrends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.A Case of Posterior Mediastinal Plasmacytoma Confounded by Community-Acquired PneumoniaPresentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature reviewEarly response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer RegistriesChallenges in multiple myeloma diagnosis and treatment.How best to use new therapies in multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?Perspectives in the treatment of multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.Incorporating novel agents in the management of elderly myeloma patients.Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.Staging and prognostication of multiple myelomaReconstruction of multiple myeloma lesions around the pelvis and acetabulum.Treatment-related symptom management in patients with multiple myeloma: a review.The serological diagnostic challenges of multiple myeloma.Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisationNovel Induction Regimens in Multiple Myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Age-related health care disparities in multiple myeloma.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
P2860
Q26859133-5EA46CCE-BC62-4900-B9B9-70F661880170Q27002668-A618000A-863E-4C40-BC79-627837DBE4A2Q28074521-C5962808-AAF8-4A75-AA0F-7FD2C7B80F5DQ30962747-E8B41905-2D4B-4987-9894-5BD9C7D23CBFQ33429115-0BC381B5-272C-4031-B061-9FC232E4B4FFQ33982728-D2BEEA98-F1DB-434A-BA69-63ECAD3D62B1Q34325722-8BE3F4E6-4AD4-4F5A-9A01-6C62E44174AFQ34539519-250C1BEC-BBD0-49F2-B45E-04CB4F3B45C8Q35104606-454197CC-FBDD-4A10-A079-34670AC33D8EQ35263009-7CC5B35D-1A42-4465-A4D4-F63E35932AF6Q35298727-ADC1B149-5A34-42D9-91B8-43266E700DF4Q35410550-1738D9B4-9C39-4A76-BC18-BEF9146F6C23Q35843835-7200DB33-F779-4EDD-A1D7-1009A64484B1Q36503079-8BF8A2EE-3550-45F2-A845-5BA943AD2248Q36536365-01D071D6-5F74-4AD1-86B6-17DB923EC780Q36611288-FE7AF887-DE0A-4E80-8675-D2ABF2BC044AQ36852225-E163C228-7596-479E-9A9C-7716B4EB6549Q37723000-9F170987-3010-4342-A1C0-D0A53A04B08EQ37761370-12250D43-494E-40AF-B522-3B613910BE9CQ37851944-00F28F31-03B6-4F2F-B2E3-F8022717AA46Q37858523-4CBA6723-2D20-4F55-90B5-12E9BB3D700EQ38000078-C98544B6-7E9B-438E-B1DA-BE1A5B2FEF9BQ38037600-C6F32D36-0176-4E0A-A4EB-D1334B81134BQ38096055-61EA7E9C-8479-49F2-89BD-1D49CC47C05EQ38098877-595AECD0-DA8C-4A76-94F6-ABB28866241BQ38108391-0E2DC778-E6C0-4978-A481-7ECA32FD6FB7Q38139989-1A142EBF-6B76-46FE-B2CB-B56E2B6B4128Q38146974-91D40D75-9CAA-45DC-95AE-0CDCEDE5D518Q38154927-77D060F1-9C7E-4585-8470-80A91C831964Q38183871-6E624DA8-A78C-40F5-B59D-1803C354EF89Q38261214-10804A3B-9A4B-446D-8B03-5BCC94AF76D2Q38342281-B957496C-5D10-464B-B69A-E1798B8BBB2DQ38351789-E8E07512-25CF-4D91-84CF-B9DC0EC2F496Q38385471-CF7F324F-C244-4AB1-AB52-8D71C98DCCD4Q38496485-7CB20827-B48F-4754-BED9-B605B01CEE55Q38567017-4F0E3203-8224-43FC-8CCB-E45EDB6BCCA1Q38630472-71484065-8C56-4D96-BC8C-2E2E1105005AQ38692424-4FA4916D-9F84-47AD-8C99-279168748FBAQ38833538-C7BE40E5-FF8A-47D0-99D4-C2DDC7977271Q39007207-4FB0ABB3-6B90-4DBE-BDA0-29FE099852E6
P2860
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
International Myeloma Working ...... ous stem cell transplantation.
@en
International Myeloma Working ...... ous stem cell transplantation.
@nl
type
label
International Myeloma Working ...... ous stem cell transplantation.
@en
International Myeloma Working ...... ous stem cell transplantation.
@nl
prefLabel
International Myeloma Working ...... ous stem cell transplantation.
@en
International Myeloma Working ...... ous stem cell transplantation.
@nl
P2093
P2860
P50
P356
P1433
P1476
International Myeloma Working ...... ous stem cell transplantation.
@en
P2093
B G M Durie
I Turesson
P2860
P2888
P304
P356
10.1038/LEU.2009.122
P577
2009-06-04T00:00:00Z
P5875
P6179
1007268714